Nanomedicines as cancer therapeutics: Current status

S. Akhter, M Ahmad, F. Ramzani, A. Singh, I. Ahmad, Z. Rahman, F.J. Ahmad, Gerrit Storm, R.J. Kok

Research output: Contribution to journalArticleAcademicpeer-review

75 Citations (Scopus)
99 Downloads (Pure)

Abstract

As of 21st century, cancer is arguably the most complex and challenging disease known to mankind and an inevitable public health concern of this millennium. Nanotechnology, suitably amalgamated with cancer research, has ushered an era of highly personalized and safer medicines which can improve cancer diagnosis and therapy. A wide variety of nanomedicines are currently under investigation, including polymeric/non-polymeric nanoparticles, dendrimers, quantum dots, carbon nanotubes, lipid- and micelle-based nanoparticles. The bases of these nanomedicines in reducing toxicity associated with cancer therapy are their ability to carry a large payload and multivalent-ligand targeting. This imparts specificity for targeting the tissues as well as bypass resistance mechanisms. The major hurdles on these future medicines are potential toxicity of nanoparticles, which imposes the need of extensive regulatory evaluation before nanomedicines could be utilized as cancer therapeutics. This review highlights nanopharmaceuticals that have been investigated in oncology for various applications (diagnosis, therapeutic delivery and theranostics). It also discusses the effects of nano-sized materials on tissues/organ functions, the possibility of overcoming multi-drug resistance by using nanomedicines and their current clinical status.
Original languageUndefined
Pages (from-to)362-378
JournalCurrent cancer drug targets
Volume13
Issue number4
DOIs
Publication statusPublished - 2013

Keywords

  • IR-90154
  • METIS-301789

Cite this

Akhter, S., Ahmad, M., Ramzani, F., Singh, A., Ahmad, I., Rahman, Z., ... Kok, R. J. (2013). Nanomedicines as cancer therapeutics: Current status. Current cancer drug targets, 13(4), 362-378. https://doi.org/10.2174/1568009611313040002
Akhter, S. ; Ahmad, M ; Ramzani, F. ; Singh, A. ; Ahmad, I. ; Rahman, Z. ; Ahmad, F.J. ; Storm, Gerrit ; Kok, R.J. / Nanomedicines as cancer therapeutics: Current status. In: Current cancer drug targets. 2013 ; Vol. 13, No. 4. pp. 362-378.
@article{7e05f33fcd3741cb868fa27cce3c2a31,
title = "Nanomedicines as cancer therapeutics: Current status",
abstract = "As of 21st century, cancer is arguably the most complex and challenging disease known to mankind and an inevitable public health concern of this millennium. Nanotechnology, suitably amalgamated with cancer research, has ushered an era of highly personalized and safer medicines which can improve cancer diagnosis and therapy. A wide variety of nanomedicines are currently under investigation, including polymeric/non-polymeric nanoparticles, dendrimers, quantum dots, carbon nanotubes, lipid- and micelle-based nanoparticles. The bases of these nanomedicines in reducing toxicity associated with cancer therapy are their ability to carry a large payload and multivalent-ligand targeting. This imparts specificity for targeting the tissues as well as bypass resistance mechanisms. The major hurdles on these future medicines are potential toxicity of nanoparticles, which imposes the need of extensive regulatory evaluation before nanomedicines could be utilized as cancer therapeutics. This review highlights nanopharmaceuticals that have been investigated in oncology for various applications (diagnosis, therapeutic delivery and theranostics). It also discusses the effects of nano-sized materials on tissues/organ functions, the possibility of overcoming multi-drug resistance by using nanomedicines and their current clinical status.",
keywords = "IR-90154, METIS-301789",
author = "S. Akhter and M Ahmad and F. Ramzani and A. Singh and I. Ahmad and Z. Rahman and F.J. Ahmad and Gerrit Storm and R.J. Kok",
year = "2013",
doi = "10.2174/1568009611313040002",
language = "Undefined",
volume = "13",
pages = "362--378",
journal = "Current cancer drug targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers",
number = "4",

}

Akhter, S, Ahmad, M, Ramzani, F, Singh, A, Ahmad, I, Rahman, Z, Ahmad, FJ, Storm, G & Kok, RJ 2013, 'Nanomedicines as cancer therapeutics: Current status' Current cancer drug targets, vol. 13, no. 4, pp. 362-378. https://doi.org/10.2174/1568009611313040002

Nanomedicines as cancer therapeutics: Current status. / Akhter, S.; Ahmad, M; Ramzani, F.; Singh, A.; Ahmad, I.; Rahman, Z.; Ahmad, F.J.; Storm, Gerrit; Kok, R.J.

In: Current cancer drug targets, Vol. 13, No. 4, 2013, p. 362-378.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Nanomedicines as cancer therapeutics: Current status

AU - Akhter, S.

AU - Ahmad, M

AU - Ramzani, F.

AU - Singh, A.

AU - Ahmad, I.

AU - Rahman, Z.

AU - Ahmad, F.J.

AU - Storm, Gerrit

AU - Kok, R.J.

PY - 2013

Y1 - 2013

N2 - As of 21st century, cancer is arguably the most complex and challenging disease known to mankind and an inevitable public health concern of this millennium. Nanotechnology, suitably amalgamated with cancer research, has ushered an era of highly personalized and safer medicines which can improve cancer diagnosis and therapy. A wide variety of nanomedicines are currently under investigation, including polymeric/non-polymeric nanoparticles, dendrimers, quantum dots, carbon nanotubes, lipid- and micelle-based nanoparticles. The bases of these nanomedicines in reducing toxicity associated with cancer therapy are their ability to carry a large payload and multivalent-ligand targeting. This imparts specificity for targeting the tissues as well as bypass resistance mechanisms. The major hurdles on these future medicines are potential toxicity of nanoparticles, which imposes the need of extensive regulatory evaluation before nanomedicines could be utilized as cancer therapeutics. This review highlights nanopharmaceuticals that have been investigated in oncology for various applications (diagnosis, therapeutic delivery and theranostics). It also discusses the effects of nano-sized materials on tissues/organ functions, the possibility of overcoming multi-drug resistance by using nanomedicines and their current clinical status.

AB - As of 21st century, cancer is arguably the most complex and challenging disease known to mankind and an inevitable public health concern of this millennium. Nanotechnology, suitably amalgamated with cancer research, has ushered an era of highly personalized and safer medicines which can improve cancer diagnosis and therapy. A wide variety of nanomedicines are currently under investigation, including polymeric/non-polymeric nanoparticles, dendrimers, quantum dots, carbon nanotubes, lipid- and micelle-based nanoparticles. The bases of these nanomedicines in reducing toxicity associated with cancer therapy are their ability to carry a large payload and multivalent-ligand targeting. This imparts specificity for targeting the tissues as well as bypass resistance mechanisms. The major hurdles on these future medicines are potential toxicity of nanoparticles, which imposes the need of extensive regulatory evaluation before nanomedicines could be utilized as cancer therapeutics. This review highlights nanopharmaceuticals that have been investigated in oncology for various applications (diagnosis, therapeutic delivery and theranostics). It also discusses the effects of nano-sized materials on tissues/organ functions, the possibility of overcoming multi-drug resistance by using nanomedicines and their current clinical status.

KW - IR-90154

KW - METIS-301789

U2 - 10.2174/1568009611313040002

DO - 10.2174/1568009611313040002

M3 - Article

VL - 13

SP - 362

EP - 378

JO - Current cancer drug targets

JF - Current cancer drug targets

SN - 1568-0096

IS - 4

ER -

Akhter S, Ahmad M, Ramzani F, Singh A, Ahmad I, Rahman Z et al. Nanomedicines as cancer therapeutics: Current status. Current cancer drug targets. 2013;13(4):362-378. https://doi.org/10.2174/1568009611313040002